CCDC71L

Across TCGA pan-cancer cohorts, CCDC71L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC71L data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCDC71L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCDC71L expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where CCDC71L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	15	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.844	.014	9	view →
HNSC	OS	Median	All	1.000	0.947	.021	8	view →
LUAD	OS	Median	II,III,IV	0.325	0.899	.002	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC71L–PDAC (DFS)

Open the PDAC breakdown →